炎症性肠病中免疫抑制剂和生物制剂所致的肝脏并发症。
Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.
作者信息
Tran-Minh My-Linh, Sousa Paula, Maillet Marianne, Allez Matthieu, Gornet Jean-Marc
机构信息
My-Linh Tran-Minh, Paula Sousa, Marianne Maillet, Matthieu Allez, Jean-Marc Gornet, Department of Gastroenterology, AP-HP, Saint Louis Hospital, 75010 Paris, France.
出版信息
World J Hepatol. 2017 May 8;9(13):613-626. doi: 10.4254/wjh.v9.i13.613.
The incidence of inflammatory bowel diseases (IBD) is rising worldwide. The therapeutic options for IBD are expanding, and the number of drugs with new targets will rapidly increase in coming years. A rapid step-up approach with close monitoring of intestinal inflammation is extensively used. The fear of side effects represents one the most limiting factor of their use. Despite a widespread use for years, drug induced liver injury (DILI) management remains a challenging situation with Azathioprine and Methotrexate. DILI seems less frequent with anti-tumor necrosis factor agents and new biologic therapies. The aim of this review is to report incidence, physiopathology and practical guidelines in case of DILI occurrence with the armamentarium of old and new drugs in the field of IBD.
炎症性肠病（IBD）在全球范围内的发病率正在上升。IBD的治疗选择正在不断扩展，未来几年具有新靶点的药物数量将迅速增加。一种对肠道炎症进行密切监测的快速强化治疗方法被广泛应用。对副作用的担忧是其使用的最限制因素之一。尽管多年来一直在广泛使用，但对于硫唑嘌呤和甲氨蝶呤而言，药物性肝损伤（DILI）的管理仍然是一个具有挑战性的情况。DILI在抗肿瘤坏死因子药物和新的生物疗法中似乎不太常见。本综述的目的是报告IBD领域中使用新旧药物时发生DILI的发病率、病理生理学及实用指南。
Zotero 插件